# Janssen - Glucose Regulation/Risp/Olanz

> **NCT00205738** · NA · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 120 (actual)

## Conditions studied

- Schizophrenia
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Risperidone, Olanzapine

## Key facts

- **NCT ID:** NCT00205738
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-07
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2014-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00205738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00205738, "Janssen - Glucose Regulation/Risp/Olanz". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00205738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*